Okamura Koichi, Yonemoto Yukio, Suto Takahito, Okura Chisa, Takagishi Kenji
Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine , Maebashi, Gunma , Japan.
Mod Rheumatol. 2015 Jul;25(4):534-9. doi: 10.3109/14397595.2014.998361. Epub 2015 Feb 11.
In recent years, the use of one or more conventional synthetic disease-modifying antirheumatic drugs has been recommended for the treatment of rheumatoid arthritis (RA). We performed a 52-week study on the efficacy and safety of iguratimod (IGU) against patients with RA in daily clinical use.
Forty-one patients were enrolled in this study, and the clinical course of RA was regularly evaluated during the 52 weeks of treatment.
The survival rate at week 52 was 53.7%. The disease activity score (DAS) 28-erythrocyte sedimentation rate, DAS28-C-reactive protein, simplified disease activity index, and clinical disease activity index were all significantly decreased at week 52. The matrix metalloproteinase-3 level was significantly decreased at week 52 by combination therapy of IGU and methotrexate. There were one case of the onset of interstitial pneumonia (IP), one exacerbation of IP, and one case of the onset of Pneumocystis jiroveci pneumonia.
IGU is effective for RA patients when used for daily clinical treatment for 52 weeks.
近年来，推荐使用一种或多种传统合成抗风湿药物来治疗类风湿关节炎（RA）。我们针对依那西普（IGU）在日常临床应用中治疗RA患者的疗效和安全性进行了一项为期52周的研究。
41名患者参与了本研究，在52周的治疗期间对RA的临床病程进行定期评估。
第52周时的生存率为53.7%。在第52周时，疾病活动评分（DAS）28-红细胞沉降率、DAS28- C反应蛋白、简化疾病活动指数和临床疾病活动指数均显著降低。通过IGU与甲氨蝶呤联合治疗，第52周时基质金属蛋白酶-3水平显著降低。有1例间质性肺炎（IP）发病、1例IP病情加重以及1例耶氏肺孢子菌肺炎发病。
IGU用于RA患者日常临床治疗52周时有效。
